Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Nevis Brands Inc C.NEVI

Alternate Symbol(s):  NEVIF

Nevis Brands Inc., formerly Pascal Biosciences Inc., provides cannabis brands throughout the United States. The Company provides products in Washington, Oregon, California, Ohio, Arizona and Colorado through partners and licensees. Its products include the flagship brand Major, which is a cannabis beverage. Major is a high-dose tetrahydrocannabinol (THC) beverage that delivers a consistent... see more

CSE:NEVI - Post Discussion

Nevis Brands Inc > > Pascal Biosciences Inc. biopharmaceutical company <
View:
Post by Pascalbios on Apr 25, 2021 8:07pm

> Pascal Biosciences Inc. biopharmaceutical company <

About

Pascal Biosciences Inc. (TSXV:PAS, FSE:6PB.F) is a biopharmaceutical company founded in 2013 to advance technology licensed from the University of British Columbia. We create additional value with programs licensed from other organizations and with our in-house discovery research. Cancer is our primary focus. Strategically, we aim to leverage our innovative technologies and experienced leadership and scientific team to develop new, effective therapeutics that will change the lives of patients.


Pascal has a strong development pipeline. Our leading cannabinoid portfolio includes a Cannabinoid for COVID-19; PAS-403, a small molecule therapeutic advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory molecule designed to enhance efficacy of checkpoint inhibitors. In addition, we are developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas.

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities